Mouse Anti-KMT2D Recombinant Antibody (2E1) (CBMAB-A5512-LY)

Dhar, S. S., & Lee, M. G. (2021). Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors. Oncotarget, 12(13), 1296.

Heward, J., Koniali, L., D’Avola, A., Close, K., Yeomans, A., Philpott, M., ... & Fitzgibbon, J. (2021). KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood, The Journal of the American Society of Hematology, 138(5), 370-381.

Alam, H., Tang, M., Maitituoheti, M., Dhar, S. S., Kumar, M., Han, C. Y., ... & Lee, M. G. (2020). KMT2D deficiency impairs super-enhancers to confer a glycolytic vulnerability in lung cancer. Cancer cell, 37(4), 599-617.

Wang, G., Chow, R. D., Zhu, L., Bai, Z., Ye, L., Zhang, F., ... & Chen, S. (2020). CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade. Cancer discovery, 10(12), 1912-1933.

Sun, P., Wu, T., Sun, X., Cui, Z., Zhang, H., Xia, Q., & Zhang, D. (2019). KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes. Biomedicine & Pharmacotherapy, 115, 108924.

Fagan, R. J., & Dingwall, A. K. (2019). COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer. Cancer letters, 458, 56-65.

Li, S. S., Jiang, W. L., Xiao, W. Q., Li, K., Zhang, Y. F., Guo, X. Y., ... & Wan, R. (2019). KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma. World Journal of Gastrointestinal Oncology, 11(8), 599.

Xiong, W., Deng, Z., Tang, Y., Deng, Z., & Li, M. (2018). Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer. Biochemical and biophysical research communications, 504(1), 129-136.

Ardeshir-Larijani, F., Bhateja, P., Lipka, M. B., Sharma, N., Fu, P., & Dowlati, A. (2018). KMT2D mutation is associated with poor prognosis in non–small-cell lung cancer. Clinical lung cancer, 19(4), e489-e501.

Lv, S., Ji, L., Chen, B., Liu, S., Lei, C., Liu, X., ... & Lu, L. (2018). Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. Oncogene, 37(10), 1354-1368.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols